Bristol Myers signs deal with Janux on T cell engager for $50M upfrontnews2026-01-22T15:15:21+00:00January 22nd, 2026|Endpoints News|
Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’snews2026-01-21T12:14:26+00:00January 21st, 2026|Endpoints News|
2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-onsnews2026-01-20T13:00:25+00:00January 20th, 2026|Endpoints News|
Pfizer to depart GSK’s ViiV as Shionogi doubles its stakenews2026-01-20T12:02:06+00:00January 20th, 2026|Endpoints News|
GSK makes $2.2B deal for RAPT and its food allergy candidatenews2026-01-20T10:34:11+00:00January 20th, 2026|Endpoints News|
#JPM26: Inside Fosun Pharma’s ambition to reach outside of Chinanews2026-01-15T16:31:32+00:00January 15th, 2026|Endpoints News|
#JPM26: Day 3 at the JP Morgan Healthcare Conferencenews2026-01-14T12:00:12+00:00January 14th, 2026|Endpoints News|
Novartis licenses radiopharma asset from Chinese biotech for $50M upfrontnews2026-01-13T12:07:22+00:00January 13th, 2026|Endpoints News|
#JPM26: Day 2 at the JP Morgan Healthcare Conferencenews2026-01-13T12:00:15+00:00January 13th, 2026|Endpoints News|
AbbVie jumps into PD-1xVEGF bispecific race, pays $650M upfront to RemeGennews2026-01-12T15:41:14+00:00January 12th, 2026|Endpoints News|
